Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective phase II clinical study to assess the efficacy of Sintilimab combined
with Bevacizumab for driving gene-negative, asymptomatic brain metastases from non-small cell
lung cancer by intracranial ORR(iORR),also iPFS,ORR and PFS.The safety and tolerability is
evaluated as well.